Skip to main content
TipRanks
Go Ultimate75% OFF

Beijing Health (Holdings) Limited (2389) AI Stock Analysis

0 Followers
HK:2389

Beijing Health (Holdings) Limited

(HKEX:2389)

Select Model
Rating:42Neutral
Price Target:HKD 0.07â–¼(-3.90% Downside)
Action:reiterated
Date:11/14/26

The score is primarily constrained by persistent losses and weak cash generation, with the conservative balance sheet providing only partial support. Technical conditions are mixed, while the negative P/E and absent dividend yield provide no valuation cushion.

Positive Factors
Low LeverageVery low leverage reduces dependence on external financing and limits the burden of interest or refinancing obligations. This gives Beijing Health greater financial flexibility to absorb operating volatility and preserve funding capacity while it works to improve profitability.
Negative Factors
Persistent UnprofitabilityDeep operating and net losses show that the current business model has not yet achieved a stable, profitable operating base. Persistent negative margins can erode equity, restrict internally funded investment, and make future financial performance highly dependent on a successful turnaround.

Beijing Health (Holdings) Limited (2389) vs. iShares MSCI Hong Kong ETF (EWH)

-20%-15%-10%-5%0%5%10%15%HK:2389+4.05%EWH+8.17%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 466.53M
Dividend Yield
―
Average Volume (3M)
436.53K
Price to Earnings (P/E)
-4.5
Beta (1Y)
0.03
Revenue Growth
-27.63%
EPS Growth
-16.33%
Country
Hong Kong
Employees
202
Sector
Healthcare
Sector Strength
51
Industry
Medical - Care Facilities

Beijing Health (Holdings) Limited Business Overview & Revenue Model

Company Description

Beijing Health (Holdings) Limited, an investment holding company, provides medical, health, and geriatric care related services and products in the People’s Republic of China. It engages in the investment and operation of general health industrial pa...

Beijing Health (Holdings) Limited Financial Statement Overview

Summary

Persistent annual losses, negative operating results, and consistently weak or negative free cash flow outweigh the company’s conservative balance sheet and recent revenue recovery.

Income Statement

22Negative

Balance Sheet

55Neutral

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue110.89M157.20M149.94M140.35M166.48M203.78M
Gross Profit17.21M42.45M35.68M38.47M46.51M46.99M
EBITDA-47.76M-77.41M-97.47M-44.19M-75.25M-10.37M
Net Income-103.47M-100.91M-116.22M-61.88M-97.70M-39.41M
Balance Sheet
Total Assets2.05B2.10B1.95B2.18B2.42B2.84B
Cash, Cash Equivalents and Short-Term Investments220.43M237.36M211.08M335.96M440.76M496.30M
Total Debt31.70M114.16M5.65M4.89M32.75M48.37M
Total Liabilities294.41M343.11M209.74M223.82M271.77M341.34M
Stockholders Equity1.67B1.66B1.72B1.89B2.04B2.29B
Cash Flow
Free Cash Flow-58.10M-18.02M-42.20M-45.10M-12.34M406.00K
Operating Cash Flow-47.70M-5.49M-35.56M-43.72M-11.19M1.99M
Investing Cash Flow108.91M154.75M-33.80M74.76M22.77M-227.83M
Financing Cash Flow-135.51M-88.80M-5.28M-68.40M-17.71M-20.46M

Beijing Health (Holdings) Limited Technical Analysis

Technical Analysis SentimentPositive
Last Price0.08

Price Trends

50DMA0.07Positive
100DMA0.08Positive
200DMA0.07Positive

Market Momentum

MACD-0.00Negative
RSI68.57Neutral
STOCH42.96Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2389, the sentiment is Positive. The current price of 0.08 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.07, and above the 200-day MA of 0.07, indicating a bullish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 68.57 is Neutral, neither overbought nor oversold. The STOCH value of 42.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2389.

Beijing Health (Holdings) Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HK:2389 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:6078HK:607866NeutralHKD 6.57B31.382.55%―1.59%-58.55%
HK:3869HK:386954NeutralHKD 442.22M-136.05-0.41%―3.16%-101.02%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HK:3886HK:388648NeutralHKD 1.22B86.190.48%1.00%-3.26%―
HK:0722HK:072242NeutralHKD 300.36M-3.89-10.76%8.80%-1.37%-334.69%
HK:2389HK:238942NeutralHKD 466.53M-4.53-6.22%―-27.63%-16.33%

* Healthcare Sector Average

Performance Comparison

-40%-20%0%HK:2389HK:3869HK:3886HK:6078HK:0722Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:2389 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:2389Beijing Health (Holdings) Limited0.080.004.05%
HK:3869Hospital Corporation of China Ltd3.20-2.68-45.58%
HK:3886Town Health International Medical Group Ltd.0.18-0.08-31.30%
HK:6078Hygeia Healthcare Holdings Co., Ltd.10.70-2.30-17.69%
HK:0722UMP Healthcare Holdings Limited0.38-0.07-15.35%

Beijing Health (Holdings) Limited Corporate Events

Beijing Health Widens Interim Loss as Revenue Slumps but FX Gains Ease Overall Hit

Aug 31, 2026

Beijing Health (Holdings) Limited reported a sharp decline in revenue for the six months ended 30 June 2026, with sales falling to HK$30.3 million from HK$76.6 million a year earlier and gross profit dropping to HK$3.8 million. Higher selling and dis...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026